SecBot SecBot
PRESS-RELEASE ·Filed Jun 16, 2026

BIOA

BioAge Labs, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

No immediate stock-moving catalyst; traders should monitor for topline Phase 2 data in H2 2026. Phase 1 hsCRP reductions were strong, but Phase 2 proof-of-concept is still highly binary and carries clinical risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$20.49
T+0 close · Jun 16, 2026 · via day close
Latest settled
−57.78%
T+60 · $8.65
Vs SPY
−58.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $20.49entry
  2. T+1 · 5mo ago −2.44%α −1.19% · $19.99
  3. T+5 · 5mo ago +8.93%α +11.16% · $22.32
  4. T+20 · 4mo ago +11.18%α +10.98% · $22.78
  5. T+60 · 2mo ago −57.78%α −58.78% · $8.65
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor) for cardiovascular risk reduction. Topline data expected H2 2026, a routine operational milestone with no financial or efficacy data disclosed.

Key Facts

  • First participant dosed in Phase 2 trial QUELL-CV evaluating BGE-102
  • Trial is randomized, double-blind, placebo-controlled, dose-ranging (30/60/90 mg QD) in ~160 participants
  • Primary endpoint: percent change from baseline in hsCRP
  • Topline data anticipated in second half of 2026
  • Phase 1 data previously showed 86% median hsCRP reduction at 60 mg and 120 mg doses

Financial Impact

No financial data in release; $882M market cap, clinical-stage company with no revenue

none

Risk Factors

  • Phase 2 may fail to replicate Phase 1 hsCRP reductions or show clinical benefit
  • Competition from other NLRP3 inhibitors and anti-inflammatory cardiovascular therapies
  • No approved products or revenue; capital needs for further development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3312476

Track record

11 reports on BIOA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
  4. Jun 16, 202621w ago Press Release Neutral 3/10 Viewing Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
  5. May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
  6. Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
  7. Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
  8. Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
  9. Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
  10. Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (11h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026